MicroRNAs as monitoring markers for right-sided heart failure and congestive hepatopathy.

Journal of Medicine and Life
Ruxandra Florentina Ionescu, Sanda Maria Cretoiu

Abstract

The last decades showed a worrying increase in the evolution of cardiovascular diseases towards different stages of heart failure (HF), as a stigma of the western lifestyle. MicroRNAs (miRNAs), non-coding RNAs, which are approximately 22-nucleotide long, were shown to regulate gene expression at the post-transcriptional level and play a role in the pathogenesis and progression of HF. miRNAs research is of high interest nowadays, as these molecules display mechanisms of action that can influence the course of evolution of common chronic diseases, including HF. The potential of post-transcriptional regulation by miRNAs concerning the diagnosis, management, and therapy for HF represents a new promising approach in the accurate assessment of cardiovascular diseases. This review aims to assess the current knowledge of miRNAs in cardiovascular diseases, especially right-sided heart failure and hepatomegaly. Moreover, attention is focused on their role as potential molecular biomarkers and more promising aspects involving miRNAs as future therapeutic targets in the pathophysiology of HF.

References

Dec 6, 2003·Science·Chang-Zheng ChenDavid P Bartel
Dec 17, 2005·Stem Cells·Anna M KrichevskyKenneth S Kosik
Oct 26, 2006·Nucleic Acids Research·Curtis AndersonRudolf Werner
Feb 13, 2007·Proceedings of the National Academy of Sciences of the United States of America·Robert W GeorgantasCurt I Civin
Jan 29, 2008·Current Stem Cell Research & Therapy·Kara M Foshay, G Ian Gallicano
Aug 13, 2008·Developmental Cell·Jason E FishDeepak Srivastava
Dec 17, 2009·Diabetes/metabolism Research and Reviews·Biao FengSubrata Chakrabarti
Feb 27, 2010·Circulation Research·Anke J TijsenYigal M Pinto
Jul 10, 2010·Nucleic Acids Research·Kai WangDavid J Galas
Sep 18, 2010·Clinical Chemistry·Jessica A WeberKai Wang
Dec 22, 2010·Circulation·Izhak Kehat, Jeffery D Molkentin
Mar 9, 2011·Proceedings of the National Academy of Sciences of the United States of America·Jason D ArroyoMuneesh Tewari
May 26, 2011·Nucleic Acids Research·Andrey TurchinovichBarbara Burwinkel
Jan 3, 2012·International Journal of Biological Sciences·Qi ZhouXuewei Li
Jan 21, 2012·Journal of Cellular and Molecular Medicine·Jue WangZhe Zheng
May 23, 2012·Protein & Cell·Jun HuSongdong Meng
Jul 24, 2012·The Journal of Clinical Investigation·Wei-Chih TsaiAnn-Ping Tsou
Aug 14, 2012·International Journal of Cardiology·Ana V VillarJ Francisco Nistal
Sep 5, 2012·Trends in Biochemical Sciences·Andrey TurchinovichBarbara Burwinkel
Mar 19, 2013·The American Journal of Pathology·Chifumi Ohyagi-HaraTadashi Kimura
May 23, 2013·European Journal of Heart Failure·Katrina L EllisA Mark Richards
Jun 19, 2013·Cardiovascular Research·Maarten Hulsmans, Paul Holvoet
Jul 11, 2013·Nature Reviews. Molecular Cell Biology·Mei XinRhonda Bassel-Duby
Jul 16, 2013·Clinical Pharmacology and Therapeutics·I ElzenaarR J van Oort
Nov 30, 2013·Cardiology Clinics·Frances L Johnson
Mar 1, 2014·Nature Communications·Fatiha TabetKerry-Anne Rye
Sep 23, 2014·Cell Death and Differentiation·L GalluzziG Kroemer
Oct 13, 2014·Journal of Hepatology·Christoph Roderburg, Tom Luedde

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Related Papers

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
Miki Nakajima
BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology
Katlin B Massirer, Amy E Pasquinelli
© 2021 Meta ULC. All rights reserved